Heather serves as the Head of Production for New River Labs. In this role, Heather oversees the processing and reporting of all submitted patient specimens, and she manages the production team, including scientists and laboratory technicians. Heather ensures that patient specimens are properly inspected, treated, and analyzed and test results are promptly delivered to the ordering physician.
Prior to New River Labs, Heather held multiple roles at Protea Biosciences. Most recently, Heather served as a senior scientist, performing sample preparation, sample analysis, and report generation activities focused on proteomic and biopharma samples. Prior to this position, she served as Laboratory Manager and was responsible for the company’s production and quality assurance efforts as well as the research and development of proteomic consumable products.
Heather received a BS degree in Biochemistry and a MS degree in Genetics and Developmental Biology from West Virginia University. Her research focused on the impact of caloric sweeteners causing various adverse metabolic and endocrine changes resulting in adolescent obesity.
Jordan serves as the Laboratory Manager for New River Labs. In this role, Jordan manages company compliance with all CLIA requirements pertaining to its clinical reference laboratory, and he serves as the company's CLIA General Supervisor. In addition, Jordan leads all company safety, certification and accreditation, and compliance efforts.
Prior to this, Jordan proudly served his country as a medical laboratory technician for six years as a Staff Sergeant in the United States Air Force before retiring in 2018. Jordan was the Medical Laboratory Supervisor for four years while stationed at Eielson Air Force Base in Alaska, where he was tasked with reporting over 125,000 patient results and maintaining compliance with over 4,500 College of American Pathologists (CAP) accreditation checklist items each year. During Jordan’s time as a Medical Laboratory Supervisor, he managed three Official CAP Inspections, resulting in overall compliance of greater than 99%.
Jordan Damko received his education and training from the Community College of the Air Force while enlisted in the United States Military.
Todd serves as the President & Chief Executive Officer of New River Labs. In this capacity, he is responsible for managing the company’s research and development, production, and administrative operations.
Prior to this, Todd was a portfolio manager at Perry Capital, a $10 billion hedge fund based in New York, and a member of the firm's investment committee. There he managed an investment team and evaluated special situation credit and equity investment opportunities. Prior to Perry Capital, Todd was a portfolio manager and the Head of Credit Research at Citadel Investment Group, a $20 billion hedge fund based in Chicago. There he managed an investment team and evaluated special situation credit, equity, and portfolio acquisition investment opportunities. Todd began his career at Credit Suisse evaluating high yield, leveraged loan, and distressed investment opportunities and then served as a founding member of the firm's Credit Opportunities Fund within its Alternative Capital Division.
Todd received a BS degree in Mechanical Engineering from the University of Florida.
Dr. Powell serves as the Chief Operating Officer for New River Labs. In this capacity, Dr. Powell leads the company’s operations, including its clinical reference laboratory, business development activities, and intellectual property strategy.
Prior to New River Labs, Dr. Powell worked for Protea Biosciences where he ultimately served as the Chief Science Officer and Vice President of Research and Development. During his tenure at Protea, he managed the new product and technology development pipeline, established external research collaborations and technology partnerships, and developed and managed the company’s intellectual property strategy.
Dr. Powell received BS degrees in Biology and Chemistry from West Virginia Wesleyan College. He then received a doctorate degree in Analytical Chemistry from West Virginia University, where his research focused on seawater proteomics.
Bailey serves as the Financial Controller for New River Labs. In this role, she oversees the accounting, finance, and risk management operations of the company.
Prior to her position at New River Labs, Bailey worked at Dixon Hughes Goodman LLP as a senior assurance associate. During this time, she led client engagements, including planning, executing, directing, and completing a variety of assurance services.
Bailey received her BS degree in Accounting from West Virginia Wesleyan College. She continued her education at West Virginia University, where she obtained her Master of Professional Accountancy. Bailey is a licensed Certified Public Accountant.
Dr. Seeley serves as the Chief Technology Officer for New River Labs. In this capacity, Dr. Seeley is responsible for evaluating new research and development pipeline opportunities, reviewing pipeline development activities, managing external research and development programs, and leading education and awareness efforts.
Prior to New River Labs, Dr. Seeley worked for Protea Biosciences where she led the company’s MALDI mass spectrometry imaging efforts, with a particular focus on clinical applications. Dr. Seeley started her career at the Mass Spectrometry Tissue Profiling and Imaging Core Laboratory at Vanderbilt University, where she initially served as a postdoctoral researcher and later served as Associate Director. During her time at Vanderbilt, Dr. Seeley worked closely with various researchers in the design and implementation of projects utilizing mass spectrometry imaging to answer clinically challenging questions, resulting in over 30 peer reviewed publications. Dr. Seeley was instrumental in establishing Vanderbilt as the first NIH-funded National Resource for Mass Spectrometry Imaging.
Dr. Seeley received her BS degree in Chemistry from Penn State University, where her research focused on mass spectrometry applications in environmental chemistry. She then received a doctorate degree in Analytical Chemistry from Purdue University, where her research focused on phosphoproteomics.
Dr. Smoot serves as the Head of Research & Development for New River Labs. In this role, Dr. Smoot leads the investigation and development of new ancillary diagnostic and prognostic tests. Once tests have attained clinical validation, Dr. Smoot transitions these tests to the company’s production team for commercial implementation.
Prior to New River Labs, Dr. Smoot served as a Scientist for Protea Biosciences. In this role, Dr. Smoot focused on the utilization of mass spectrometry for the purposes of protein characterization.
Dr. Smoot received her BS degree in Biology from Shippensburg University. She continued her education at West Virginia University, where she received a doctorate degree in Genetics and Developmental Biology. Her research focused on understanding the synthesis of various fungal mycotoxins.